Sponsored by Sublin Therapeutics 1 Oct 2024 Sublingual delivery: the future for GLP-1 receptor agonists Discover how GLP-1 receptor agonists, now thriving in obesity treatment, could benefit from a more patient-friendly sublingual delivery method. October 1, 2024 - 7 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
In Depth 25 Sep 2024 How Pfizer’s decision in the ’90s cost them a stronghold in the GLP-1 market Discover an untold biotech story and find out how Pfizer missed an opportunity in the GLP-1 market because of an exit in the ’90s. September 25, 2024 - 9 minutesmins - By Jennifer Tsang Share WhatsApp Twitter Linkedin Email
Best in Biotech 5 Sep 2024 Six biotech companies that could revolutionize obesity treatments In this article, we take a look at six biotechs focused on bringing drugs to treat obesity to the market. September 5, 2024 - 9 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 28 Aug 2024 GLP-1 shortage: Can biotech companies keep up with rising demand? How is the biotech industry responding to the GLP-1 drug shortage? We asked experts in the field to answer this question. August 28, 2024 - 6 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Sponsored by KBI Biopharma 16 Jul 2024 How a microbial expression update is driving biotech innovation Discover how microbial expression systems are revolutionizing protein production for next-gen therapies like antibodies and peptides. July 16, 2024 - 7 minutesmins - By Ute Boronowsky Share WhatsApp Twitter Linkedin Email
In Depth 25 Mar 2024 Beyond Wegovy: Could Novo Nordisk’s new experimental weight loss pill be even better? Discover how Novo Nordisk’s new experimental obesity pill, amycretin, could be even more efficient for weight loss than Wegovy. March 25, 2024 - 4 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 4 Jan 2024 Can GLP-1 agonists, the miraculous obesity drugs, treat cardiovascular diseases? Discover how GLP-1 agonists, known for treating diabetes and obesity, are now being studied for their potential in tackling heart diseases. January 4, 2024 - 6 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 30 Nov 2023 Could an Alzheimer’s vaccine make treatment more affordable? Alzheimer’s research has come a long way since the disease was first identified more than a century ago. Now, as treatments have been developed to reduce the harmful proteins in the brain that are associated with Alzheimer’s, vaccine trials are underway to eliminate these proteins. But how far along are these vaccines in the clinic? […] November 30, 2023 - 7 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 22 Nov 2023 Apellis’ Syfovre vs Astellas’ Izervay: the battle for a geographic atrophy treatment Until the approval of Apellis’ Syfovre earlier this year, there was no treatment for geographic atrophy. Shortly after, Astellas’ Izervay was also approved for the eye condition. Now, as the only two companies with approved geographic atrophy treatments, there appears to be an ongoing rivalry between them to see who can come out on top […] November 22, 2023 - 8 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
Podcast 11 Aug 2023Beyond Biotech podcast 58 – Pepteins To learn about pepteins, we had a conversation with Christian Schwarz, CEO and co-founder of Numaferm. Numaferm is a German biotech company, specializing in the production of pepteins, which are an underdeveloped class of molecules located between peptides and proteins (with a length of 30-300 amino acids). Pepteins are non-structured and complex posing a […] August 11, 2023 Share WhatsApp Twitter Linkedin Email
News and Trends 7 Jul 2023 Swedish researchers look to peptides to destroy viruses A new study from Sweden shows how a type of peptide from a lactic acid bacterium destroys viruses, including coronavirus. The findings have resulted in a Swedish patent, with an international patent pending. “We’re hoping for a quick turnaround to allow this discovery to be utilised in antiviral treatments and as a complement to vaccine,” […] July 7, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 1 Jun 2023 Swiss researchers develop new class of antibiotics to fight resistant bacteria Health professionals are in urgent need of new antibiotics to tackle resistant bacteria. Researchers at the University of Zurich (UZH), in Switzerland, and the company Spexis, have now modified the chemical structure of naturally occurring peptides to develop antimicrobial molecules that bind to novel targets in the bacteria’s metabolism. Each year, more than five million […] June 1, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email